REG - Sareum Holdings PLC - Update on financial and operational progress

Sareum HoldingsAnnouncement

16/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230816:nRSP4212Ja&default-theme=true

RNS Number : 4212J  Sareum Holdings PLC  16 August 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum updates on financial and operational progress

·    Equity Prepayment Facility of up to £5.0 million agreed with
RiverFort Global Opportunities PCC Ltd which provides funding towards the
Phase 1 trial of SDC-1801

·    Phase 1a clinical trial of lead programme SDC-1801 progressing well
in Australia

·    Multiple Ascending Dose escalation phase expected to commence in Q3
2023, subject to Safety Review Committee approval

Cambridge, UK, 16 August 2023 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, today provides a business update
ahead of its full year results for the year ended 30 June 2023, and updates on
the progress of its SDC-1801 Phase 1a clinical trial and other operations.

Dr Tim Mitchell, CEO of Sareum, commented:

"With a newly agreed funding facility designed to support Sareum through the
Phase 1 study of its lead programme, SDC-1801, and good initial progress on
the Phase 1a part of the trial, Sareum has begun the new financial year with
significant momentum.

"Pending the continuing good progress of the single ascending dose stage and
review of the results by the safety review committee, we expect Part 2 of the
trial, the multiple ascending dose, to commence in Q3 2023.

"We remain fully focused on bringing SDC-1801 to patients and are encouraged
both by the growing commercial momentum around the TYK2/JAK1 space and by the
progress of our trial. We look forward to progressing into the next phase of
this trial as soon as possible and will update investors accordingly."

OPERATIONAL HIGHLIGHTS - STRONG CLINICAL PROGRESS

SDC-1801 (autoimmune disease)

SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new
therapeutic for a range of autoimmune diseases with an initial focus on
psoriasis, an autoimmune condition affecting the skin.

SDC-1801 is currently undergoing a Phase 1a clinical trial designed to
investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of
an oral formulation of SDC-1801 in healthy subjects (trial ID
ACTRN12623000416695p). This is a randomised, placebo-controlled trial, with
single and multiple ascending oral dose studies.

Recruitment of participants has been progressing to plan and the trial safety
committee will make a decision shortly as to whether the study can progress to
Part 2 of the Phase 1a trial, the multiple ascending dose stage. Subject to a
positive decision, this is expected to commence in Q3 2023. The safety
committee will also establish the maximum dose to move forward into cohort A
of Part 2, based on the safety and pharmacokinetic data observed to date in
Part 1 (single ascending dose stage). Part 2 will begin in parallel with
additional planned dose escalation in Part 1 of the study.

Full safety data from the Phase 1a trial are expected to be available during
the first half of 2024 and, provided satisfactory results continue to be
obtained, and funding is available under the RiverFort Equity Prepayment
Facility or otherwise, a Phase 1b clinical study is expected to commence as
soon as possible thereafter in psoriasis patients, with a readout expected
before the end of 2024, subject to recruitment and progress.

Psoriasis is an autoimmune dermatological condition affecting more than 60
million adults worldwide, with a market size for potential treatments
estimated to be worth more than US$30.0 billion. Sareum believes that
TYK2/JAK1 inhibition offers potential for increased efficacy in psoriasis,
compared with existing approved therapies.

TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune
system and has strong clinical validation in psoriasis and psoriatic
arthritis.

SDC-1802 (cancer immunotherapy)

Sareum continues to work on the translational studies needed to define the
optimal cancer application prior to completing toxicology and manufacturing
studies.

PATENT UPDATES

In June 2023, the Company announced that The China National Intellectual
Property Administration (CNIPA) has officially issued patent number
CN113056456, safeguarding SDC-1801 and medical applications of it in treating
inflammatory or immune disorders. This is the first patent grant issued to
Sareum for SDC-1801 in any territory. Patent applications in Europe
(EP3864009), the US (US2021387981) and other territories are still under
review.

The Company also announced in June 2023 that the United States Patent and
Trademark Office (USPTO) has formally granted patent number US 11,673,870
specifically covering the treatment of autoimmune disorders with SDC-1802 and
several analogues. While Sareum has previously secured international patents
providing comprehensive protection for the compound SDC-1802, this patent
extends its scope in the US beyond immuno-oncology.

This follows the granting of a patent, in April 2022, for protecting the
SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to
treat T-cell acute lymphoblastic leukaemia (T-ALL - a cancer of a particular
type of white blood cell called a T lymphocyte) and other cancers that are
dependent on TYK2 kinase for survival.

SRA737: A Selective Chk1 inhibitor

As announced in March 2023, Sierra Oncology, Inc ("Sierra"), has completed the
return of the Clinical Study Reports and other associated documents and data
related to SRA737 to Sareum's co-development partner, the CRT Pioneer Fund LP
("CPF").

As the major partner, CPF is taking the lead in evaluating potential further
development opportunities for SRA737 and further updates will be provided as
appropriate.

STRENGTHENED CASH POSITION AND RESULTS FORECAST

Sareum had a cash position of approximately £1.0 million as at 30 June 2023
(cash of £2.9 million as at 31 December 2022 and £4.3 million as at 30 June
2022).  In August 2023, Sareum agreed terms on an Equity Prepayment Facility
of up to £5.0 million with RiverFort Global Opportunities PCC Ltd (the
"Facility"), and as part of this, received an initial deposit of £2.0
million, net of associated costs, on 4 August 2023.

The Company intends to use the Facility, if fully drawn, together with the
receipt of anticipated tax credits, estimated to be in the region of £1.6
million, to complete the Phase 1a/b clinical development of the Company's lead
candidate SDC-1801, which is expected to be a primary catalyst for driving
shareholder value, and for general working capital to Q4 2024.

Whilst still subject to audit, the loss for the year to 30 June 2023 is
expected to be around £3.3 million after tax, (2022: £2.2 million), which is
in-line with market expectations and reflects the increased costs associated
with setting up for and commencing clinical studies.

- Ends -

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   0203 709 5700

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFERTFIELIV